Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI
Academic source · Nature Biotechnology
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What the paper reports
The AGENT platform combines Bayesian optimization with high-throughput experiments to identify thermostable mRNA-LNP formulations through six iterations in approximately one month. Solid-state model formulations based on SM-102 and ALC-0315 retained biological activity after more than two months at 37°C. Animal immunogenicity supported further development, but these formulation-specific findings do not eliminate cold-chain requirements for mRNA products generally.
Why this paper is included
Illustrates efficient formulation optimization for thermostability; real products require long-term potency, transport, reconstitution, and safety data under their intended conditions.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections